Vinay Saluja
Vinay Saluja
Head Drug Product Lead (Late Stage Biologics Pharmaceutical Dev.), Novartis, Austria
Verified email at novartis.com
Title
Cited by
Cited by
Year
Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses …
JP Amorij, V Saluja, AH Petersen, WLJ Hinrichs, A Huckriede, HW Frijlink
Vaccine 25 (52), 8707-8717, 2007
1632007
A comparison between spray drying and spray freeze drying to produce an influenza subunit vaccine powder for inhalation
V Saluja, JP Amorij, JC Kapteyn, AH de Boer, HW Frijlink, WLJ Hinrichs
Journal of Controlled Release 144 (2), 127-133, 2010
1592010
Towards tailored vaccine delivery: needs, challenges and perspectives
JP Amorij, GFA Kersten, V Saluja, WF Tonnis, WLJ Hinrichs, B Slütter, ...
Journal of controlled release 161 (2), 363-376, 2012
1162012
Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl) 1H-imidazole] in renal tubular cells …
J Prakash, M Sandovici, V Saluja, M Lacombe, RQJ Schaapveld, ...
Journal of Pharmacology and Experimental Therapeutics 319 (1), 8-19, 2006
622006
Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: impact of formulation on physicochemical and immunological characteristics
M Tafaghodi, V Saluja, GFA Kersten, H Kraan, B Slütter, JP Amorij, ...
Vaccine 30 (36), 5341-5348, 2012
562012
Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant
V Saluja, JP Amorij, ML van Roosmalen, K Leenhouts, A Huckriede, ...
The AAPS journal 12 (2), 109-116, 2010
562010
Preservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures
F Geeraedts, V Saluja, W ter Veer, JP Amorij, HW Frijlink, J Wilschut, ...
The AAPS journal 12 (2), 215-222, 2010
532010
Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles
V Saluja, MR Visser, W Ter Veer, ML Van Roosmalen, K Leenhouts, ...
Vaccine 28 (50), 7963-7969, 2010
262010
Stability of lysozyme in aqueous extremolyte solutions during heat shock and accelerated thermal conditions
C Avanti, V Saluja, ELP van Streun, HW Frijlink, WLJ Hinrichs
PLoS One 9 (1), e86244, 2014
242014
Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles
V Saluja, MR Visser, ML Van Roosmalen, K Leenhouts, A Huckriede, ...
European journal of pharmaceutics and biopharmaceutics 76 (3), 470-474, 2010
182010
Evaluation of the stability of extemporaneously prepared ophthalmic formulation of mitomycin C
T Velpandian, V Saluja, AK Ravi, SS Kumari, R Mathur, N Ranjan, ...
Journal of Ocular Pharmacology & Therapeutics 21 (3), 217-222, 2005
142005
Bioanalysis and pharmacokinetics of the p38 MAPkinase inhibitor SB202190 in rats
J Prakash, V Saluja, J Visser, F Moolenaar, DKF Meijer, K Poelstra, ...
Journal of Chromatography B 826 (1-2), 220-225, 2005
112005
Dried influenza vaccines: over the counter vaccines
V Saluja, WLJ Hinrichs, HW Frijlink
Human Vaccines 6 (10), 854-856, 2010
32010
Novel perspectives for influenza vaccine formulation and administration
V Saluja
12010
Over the counter vaccines: Dried influenza vaccines
V Saluja, W Hinrichs, H Frijlink
Human Vaccines & Immunotherapeutics 6 (10), 854-856, 2010
2010
Novel perspectives for influenza vaccine formulation and administration: L. lactis cell wall derived adjuvant, stable dry powder vaccines and mucosal vaccine delivery
V Saluja
2010
The system can't perform the operation now. Try again later.
Articles 1–16